Rick Simpson Oil (RSO) in Duval County: The Complete Guide by OilWell Cannabis

Here in Duval County, we’ve watched the cannabis conversation evolve from whispers in Riverside to open discussions at the Mayo Clinic Jacksonville. We’ve seen neighbors in Ponte Vedra Beach search for alternatives to opioid prescriptions, veterans near Naval Air Station Jacksonville look for PTSD relief, and cancer patients throughout our community seek options beyond what conventional medicine offers. This guide exists for every one of you—whether you’re sitting in a doctors’ office in San Marco, researching at home in Mandarin, or exploring options with a loved one in Orange Park.

ABOUT RICK SIMPSON AND TRADITIONAL RSO

Who is Rick Simpson?

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, scientist, or medical professional—he was a power engineer and maintenance worker, a working-class tradesman whose journey into cannabis began with personal suffering and a deep distrust of the medical system that failed him.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. According to Simpson, the medications prescribed either didn’t help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused.

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, in which THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became a foundational reference point in Simpson’s later advocacy, even though its findings were never replicated in controlled human cancer trials.

The pivotal moment came in 2003. Simpson reported that three bumps on his arm were diagnosed by his doctor as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil.

Important context: Simpson’s account is presented here as his personal testimony. The absence of clinical documentation, controlled observation, or independent medical confirmation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement.

The Crusade—Spreading the Oil

After his 2003 experience, Simpson committed himself fully to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free to cancer patients and others in his community, charging nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and others.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials from people he had treated, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. Within cannabis communities, it was foundational—for many people, Run From The Cure was their introduction to the concept of concentrated cannabis oil as medicine.

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005 and 2009, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Facing continued legal pressure, Simpson eventually left Canada and relocated to Europe, living in Croatia and later the Netherlands, where he continued his advocacy from abroad.

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, detailing his personal experience, oil-making process, and broader philosophical views on cannabis, medicine, and institutional suppression. He also maintained phoenixtears.ca as his primary online platform for information and advocacy.

Throughout his public career, Simpson maintained that cannabis oil—particularly high-THC oil made according to his specific method—could cure cancer and many other diseases, and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge to protect their financial interests.

Important context: Simpson’s conspiratorial framing is noted here without endorsement or dismissal. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding why RSO became culturally significant.

The Traditional RSO Protocol—Simpson’s 60-Gram, 90-Day Regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver a total of 60 grams (approximately 60 mL) of concentrated cannabis oil over roughly 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions.

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration Schedule

• Week 1: Begin with a dose approximately the size of half a grain of dry rice—roughly 10 to 15 milligrams of oil—taken three times per day (morning, afternoon, and before bed). Total daily intake: approximately 30 to 45 milligrams. Simpson emphasized that initial doses should be very small to allow the body to begin adjusting to the psychoactive effects of THC.

• Weeks 2 through 5: Double the dose approximately every four days. The purpose of the slow ramp-up was to build THC tolerance gradually and minimize disruption from psychoactive effects. By the end of this escalation period—roughly four to five weeks—the target was to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.

• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, and continue until the full 60 grams have been consumed.

Administration Methods

• Primary method—oral: Simpson recommended placing the dose directly under the tongue (sublingual) or swallowing it. He considered oral ingestion the most important route for systemic absorption and the primary method for internal cancers and other systemic conditions.

• Secondary method—topical: For skin cancers and external lesions, Simpson recommended applying the oil directly to the affected area, covering it with a bandage, and changing the bandage every three to four days. He combined topical application with oral dosing for skin cancers.

• Not recommended as primary—inhalation: Simpson did not recommend smoking or vaporizing the oil as a primary treatment method. He acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained that the oral route was necessary for the sustained, high-dose exposure he considered therapeutically essential.

Tolerance and Psychoactive Effects

• Simpson maintained that patients would develop significant tolerance to the psychoactive effects of THC within approximately three to four weeks of consistent dosing at escalating levels.
• He considered the euphoric, sedating, or disorienting effects a minor and temporary side effect and strongly urged patients not to let the high discourage them from continuing the protocol.
• He recommended that patients take their initial doses at night or before bed to sleep through the most intense psychoactive effects during the early titration phase.
• Simpson also recommended that patients avoid driving or operating machinery during the titration period and that they inform family members about what to expect.

Post-Protocol Maintenance

After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely. He considered this ongoing low-dose maintenance important for long-term health and cancer prevention.

Dietary and Lifestyle Recommendations

Simpson also advocated for dietary changes alongside the oil protocol, including reducing sugar intake, avoiding processed foods, and improving overall nutrition. He was not specific or systematic about dietary protocols compared to his highly detailed oil protocol—dietary advice was secondary and general.

Important Context for Evaluating This Protocol

This protocol was designed by one person based on his personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or any formal research process. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or even well-documented case series evaluating this specific 60-gram/90-day protocol for any cancer type or any other condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content per gram of traditional RSO varied widely depending on the starting plant material and extraction technique.
• Very high THC exposure. At the peak dosing phase, patients were consuming roughly 1 gram of high-THC oil per day. Assuming traditional RSO contained 60 to 90 percent THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day—a dose far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder.
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment—potentially in place of proven therapies—introduces harm that extends beyond the oil itself.

What is Traditional Rick Simpson Oil—The Product?

Traditional RSO refers to the specific type of concentrated cannabis oil that Simpson made and advocated for. It was defined not by lab specifications or regulatory standards but by his method and materials.

Source Material

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains for cancer treatment, believing that indica strains produced better therapeutic outcomes. He grew his own cannabis or sourced it from growers he trusted. There was no strain standardization—the starting material varied by availability and growing season.

Extraction Solvent

Simpson originally used naphtha—a petroleum-based solvent commercially available as lighter fluid, Varsol, or similar products. He later also endorsed 99 percent isopropyl alcohol as an acceptable alternative. He explicitly warned against using other solvents, including butane or acetone, due to safety and purity concerns. Neither naphtha nor isopropyl alcohol is a food-grade solvent, which is a significant safety issue.

Extraction Process

1. Dry or semi-dry cannabis plant material was placed in a container (typically a bucket).
2. The material was covered with solvent and agitated or stirred for several minutes to dissolve cannabinoids and other fat-soluble compounds from the plant.
3. The solvent was poured off through a filter, typically cheesecloth or a similar mesh material, into a separate collection vessel.
4. The process was repeated a second time with fresh solvent on the same plant material to extract remaining cannabinoids.
5. The combined solvent washes—now a dark, cannabinoid-rich liquid—were placed in a rice cooker or similar open-vessel heating device.
6. The solvent was evaporated at relatively low heat. Simpson recommended a rice cooker specifically because it maintains a temperature range that evaporates the solvent without exceeding the point at which cannabinoids degrade significantly. However, this temperature was still high enough to decarboxylate THCa into THC and to destroy most volatile terpenes.
7. As the solvent evaporated, a thick, dark oil remained at the bottom of the vessel.
8. The final oil was transferred into oral syringes for storage and dosing.

Appearance and Physical Characteristics

Traditional RSO was an extremely dark—nearly black—thick, viscous, tar-like oil. It had a strong cannabis odor and could carry a faint solvent-residual smell depending on how thoroughly the solvent was purged. The consistency was sticky and difficult to handle at room temperature but became more fluid when warmed slightly.

Cannabinoid Profile

• Primarily decarboxylated delta-9 THC. The heat involved in solvent evaporation converted essentially all THCa in the extract into delta-9 THC. Traditional RSO was therefore an activated, THC-dominant product.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG, and other minor cannabinoids the source strain contained were present at their natural ratios, but these were not controlled, measured, or targeted.
• No ratio control. There was no ability to adjust or standardize specific cannabinoid ratios. The profile was entirely determined by the genetics and growing conditions of the source plant.
• Estimated THC content. Depending on starting material, traditional RSO likely ranged from approximately 60 to 90 percent total THC by weight, though this was never lab-verified in the traditional production context.

Terpene Content

Minimal to none. The combination of solvent extraction (which dissolves terpenes into the solvent along with cannabinoids) and the subsequent high-heat evaporation process (which volatilizes terpenes at temperatures well below cannabinoid degradation thresholds) meant that traditional RSO was effectively stripped of its terpene content. This is a significant distinction from modern formulations that deliberately preserve or reintroduce terpenes.

Standardization and Testing

None. Every batch of traditional RSO was different because it depended entirely on the starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature and duration, and the individual maker’s process. Simpson operated before cannabis legalization and the standardized lab-testing infrastructure that came with it. There was no Certificate of Analysis, no cannabinoid quantification, and no contaminant screening.

Residual Solvent Risk

This is one of the most significant safety concerns with traditional RSO production. Naphtha and isopropyl alcohol are not food-grade solvents. Naphtha in particular is a complex mixture of petroleum hydrocarbons that may contain benzene, toluene, xylene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging—which is very difficult to verify without analytical chemistry equipment—leaves potentially harmful residues in the finished oil. Modern extraction methods use food-grade ethanol or supercritical CO₂ specifically to address this problem.

Simpson’s Claims vs. the Evidence Record

Rick Simpson made expansive therapeutic claims about his oil. He stated that RSO could cure cancer—including terminal cases—and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions. He was adamant, consistent, and public about these claims throughout his advocacy career.

It is important to evaluate these claims against the actual evidence base, using the same standards applied throughout this document.

What Simpson Was Not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally—with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the Preclinical Literature Shows

The preclinical cannabinoid-cancer literature does exist, and it is scientifically interesting:

• In vitro studies have demonstrated that THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis (blood vessel formation that feeds tumors) in certain cancer cell lines.
• Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids.
• These findings have generated legitimate scientific interest and ongoing research.

What the Preclinical Literature Does Not Show

• These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast, well-documented across all of oncology research, and especially relevant here.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been conducted, but they have been exploratory, small, and have not produced the kind of results that would support cancer-cure claims.

Institutional Positions

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment.
• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting.
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• NCCIH explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS—not cancer cure.

What Simpson Got Right

Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing that conversation. His advocacy—however scientifically imprecise—helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term RSO itself remains the most recognized name for full-spectrum cannabis extract in the consumer vocabulary. These contributions are real and historically significant.

What He Overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as a primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature. Simpson’s absolute certainty about curative claims, while understandable from a personal-experience perspective, exceeded what the evidence could support and still exceeds it today.

The Legacy of Rick Simpson and the Evolution of Modern RSO

The term RSO is now used broadly—and often loosely—across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic.

Simpson himself has been critical of commercial products that use the RSO name while departing significantly from his original method and philosophy. He has publicly stated that many products sold as RSO do not meet his standards and that the commercialization of cannabis oil contradicts his original intent. Simpson’s model was explicitly anti-commercial—he gave the oil away for free and urged others to make their own rather than buy from companies.

This philosophical tension is worth acknowledging. Simpson believed in a do-it-yourself, free-access model in which anyone could grow cannabis, extract the oil, and treat themselves or their loved ones without corporate or governmental intermediaries. The modern cannabis industry has done something very different: it has commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents an improvement (through quality control, lab testing, and dosing precision) or a betrayal (through profit extraction and regulatory gatekeeping) depends on one’s perspective, and the cannabis community remains divided on this question.

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas in this document.

Traditional RSO vs. Modern Formulated RSO

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s Formulas Diverge from Traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways:

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew or sourced. OilWell’s formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited.
• Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. OilWell includes live terpenes at 5% with a specific seven-terpene profile—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing.
• THCa as a separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC.
• Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC—often 60 to 90% of total cannabinoid content. OilWell’s sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing the remaining cannabinoid content across CBD, CBG, CBN, and CBC. This reflects the broader cannabinoid research landscape rather than a single-compound dominance model.
• Product format innovation. Simpson envisioned only one format: an oral oil administered from a syringe. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles.

Solvent Safety and Extraction Evolution

Traditional RSO production used naphtha or isopropyl alcohol—neither of which is food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging—which is very difficult to verify without analytical chemistry equipment—leaves potentially harmful residues in the finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and the finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. This is one of the most straightforward improvements that the modern regulated cannabis industry has made over the traditional RSO production model.

The Decarboxylation Question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker—typically sustained at or near the boiling point of the solvent—was sufficient to convert essentially all THCa in the extract into delta-9 THC. As a result, the acidic cannabinoids that exist abundantly in raw cannabis plant material were lost as distinct compounds in traditional RSO.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by the THCa evidence profile, which notes that THCa itself does not produce the psychoactive effects associated with THC but that its interpretation depends on route, temperature, processing, and storage—because THCa can convert to THC under heating or over time.

Terpene Loss in Traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin to volatilize at temperatures between 21 and 157°C, with many of the most abundant terpenes having boiling points below 180°C. The traditional RSO production process destroyed terpenes in two ways: first, by dissolving them into the solvent wash along with cannabinoids; and second, by evaporating them off during the high-heat solvent-removal phase.

This meant that traditional RSO was essentially a cannabinoid-only product, despite being derived from a terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds the source cannabis contained were lost in production.

OilWell’s formulas specify live terpenes at 5% with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each of these terpenes has its own evidence profile. The entourage-effect literature provides the theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

Evidence Standards Then and Now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and throughout most of the world. There was no regulatory framework for cannabis products, no standardized testing infrastructure, no legal pathway for clinical research on cannabis oil protocols, and no peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected the constraints of that era. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense. This is not necessarily a moral failing—it is a description of the environment in which he operated.

This document takes a fundamentally different approach. The GENERAL KNOWLEDGE section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. The intent is to honor the historical origin of RSO while committing to the standards of modern cannabinoid science. Where Simpson relied on personal testimony, this document relies on published literature and institutional sources.

Simpson’s Protocol vs. Modern Dosing Considerations

Simpson’s 60-gram/90-day protocol was designed around a crude, single-strain, THC-dominant extract with no standardized potency. A direct comparison between Simpson’s dosing recommendations and dosing with a modern, standardized, multi-cannabinoid formulation is not straightforward—the products are fundamentally different.

Several key differences illustrate why:

• Cannabinoid concentration. OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios. Simpson’s oil was approximately 60 to 90% delta-9 THC. OilWell’s formula distributes 16,590 mg of total cannabinoids across CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—a completely different pharmacologic profile.
• Terpene presence. Simpson’s oil had no terpenes. OilWell’s formula includes live terpenes at 5%, which may influence absorption, effect, and tolerability.
• Delta-9 THC exposure. Simpson’s protocol at peak dosing delivered approximately 600 to 900 mg of delta-9 THC per day. OilWell’s sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making the per-dose delta-9 THC exposure dramatically lower.

Future dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by the per-compound evidence in the GENERAL KNOWLEDGE section and by responsible titration principles that account for the safety profile of each individual cannabinoid.

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The Origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts—vibrant culture and a thriving retail sector, yet deeply affected by poverty and limited opportunities outside of the retail and healthcare industries. Reynosa, on the other hand, is an industrial hub plagued by violence and cartel activity, making it a harsh environment for anyone growing up there.

Colin’s childhood in McAllen was marked by exposure to both the opportunities and the challenges of life along the border. Early on, he learned to hustle, taking on risky work in transporting items across the border for various groups. Those early experiences exposed him to the complexities and dangers of life in that region. A lot of his best friends have been killed or are in prison because of the associated dangers. He has faced every form of violence imaginable, both in the streets and across the border. By sixteen, one way or another, he had to leave home for good.

Despite the dangers, Colin did not fall into the darkest paths available to him, like selling harder substances. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—would eventually define OilWell’s approach.

Bentley’s Story—From Paralysis to Playing

The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet—he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said the pain medications would destroy his internal organs, causing him more pain and suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. Colin had already faced too much loss and seen too much suffering in his life. Bentley was a fighter, just like him, and Colin was not ready to let him go. In a desperate search for alternatives, he stumbled upon the healing properties of CBD—through a question that changed everything.

A kind-hearted rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience—but it was recreational. Getting high. He had never explored the therapeutic and medicinal applications. Jessica’s question exposed a blind spot that would become a mission.

Determined to save Bentley, Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline—and it was hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. It was a miracle. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect—dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Multi-Cannabinoid Synergy—Single Cannabinoids Weren’t Enough

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into the world of cannabis beyond just getting high. It became a mission to create real solutions that help alleviate pain and suffering, not just for pets but for people as well. Bentley’s story is the foundation of OilWell Cannabis, driving its commitment to quality, innovation, and compassionate care.

Colin’s Personal Journey—PTSD, Benzo Addiction, and Peace Gummies

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a feat that is notoriously difficult and dangerous—using the cannabinoid knowledge he had developed keeping Bentley alive. The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 Recognition—Houston’s Go-To Cannabis Authority

ABC13 KTRK Houston—Houston’s number-one news source—featured Colin Valencia and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering. Colin was repeatedly selected as the primary industry expert for cannabis policy and product coverage in America’s fourth-largest city.

Colin’s quote from the first ABC13 feature in September 2019 captures the OilWell philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). The company has been operating since 2019, generates approximately one million dollars in annual revenue, maintains a near-5.0 Google rating, and is Texas DSHS licensed. OilWell’s products are not mass-produced—they are carefully crafted with a personal touch, from the artwork on the packaging to the formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only OilWell’s own recipes and ideas. Colin brings Houston grit, McAllen roots, and a builder’s mindset to the company, but the posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

The OilWell RSO Philosophy

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision.

Four core principles define OilWell’s approach, each aligning with and evolving Simpson’s original ethos:

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. OilWell ships nationwide across the United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; OilWell built a product and distribution model that makes that accessible legally.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. The customer decides whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; OilWell engineered a product that puts that control in the customer’s hands through chemistry rather than rhetoric.

3. Open-source formulas. OilWell publishes their complete formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford the product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; OilWell adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured product and publishing the recipe.

4. Evidence-informed, not evidence-overstating. The GENERAL KNOWLEDGE section in this document represents OilWell’s commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; OilWell has that access and uses it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill Compliance and the THCa Legal Framework for Duval County

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This legal framework is the foundation of OilWell’s RSO product design.

For Duval County residents, this means our products are legal under Florida state law and federal law. Florida’s hemp program, administered by the Florida Department of Agriculture and Consumer Services (FDACS), aligns with the Farm Bill’s 0.3% delta-9 THC threshold. You can legally purchase, possess, and use OilWell’s RSO throughout Jacksonville, the Beaches, Mandarin, Riverside, San Marco, and every neighborhood in Duval County.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—3 milligrams per milliliter—well under the 0.3% threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and in Florida.

THCa—tetrahydrocannabinolic acid—is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance of this framework is substantial for Duval County residents. The customer can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in the formula, this produces approximately 1,405 milligrams of total delta-9 THC—giving the product psychoactive potency comparable to traditional illegal RSO, entirely at the customer’s discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). The customer controls the decision. The product is legal everywhere all component cannabinoids are legal, which enables shipping to Duval County and throughout Florida.

Important legal notice for Duval County customers: THCa converts to delta-9 THC when heated. Florida law, like federal law, focuses on delta-9 THC content at the point of sale. However, Duval County residents are responsible for understanding and complying with local ordinances. While Jacksonville and Duval County follow Florida’s hemp laws, we always recommend checking with local authorities if you have specific concerns. OilWell ships with full documentation, Certificates of Analysis, and receipts.

Open-Source Formulas—Why OilWell Publishes Everything

OilWell publishes our complete RSO formulas—every cannabinoid, every milligram amount, every percentage—in public documents including this one. The RSO Sublingual Oil formula and RSO Vape Cartridge formula are detailed in full later in this guide.

The rationale is straightforward: if someone in Duval County cannot afford OilWell’s products—$129.99 for the sublingual oil, $49.99 for the vape cartridge—they can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make their own version. The formulas in the RSO Sublingual Oil and RSO Vape Cartridge sections are the open-source formulas.

This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. OilWell adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

As Colin Valencia said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The open-source philosophy did not start with RSO—it started with Bentley. On the About Us page, Colin published the actual CBD golden paste recipe that saved Bentley’s life, so that any pet owner in Duval County or anywhere else facing a similar crisis could make it themselves:

CBD Golden Paste Recipe for Pets—The Original Open-Source Formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix the turmeric and water. In a saucepan, combine the turmeric powder and water, stirring over low heat. Stir continuously until it forms a thick paste. This should take about 7 to 10 minutes. Add a little more water if it becomes too thick.
2. Add the coconut oil and pepper. Once you have a thick paste, add the coconut oil and freshly ground black pepper. Stir until all ingredients are thoroughly mixed.
3. Cool and store. Allow the paste to cool, then transfer it to a jar with a lid. Store it in the refrigerator for up to two weeks.
4. Dosage. Add a small amount of CBD oil to the paste before giving it to the pet, adjusting the dosage based on their weight and health needs. Start with a low dose and gradually increase as needed.

Serving suggestion: Mix a small amount of the golden paste with the pet’s food once or twice a day. Monitor the pet for any changes and consult with a veterinarian if there are any concerns. Always consult with a veterinarian before starting any new supplement regimen for a pet.

The Decarboxylation Choice—Patient-Controlled Potency for Duval County

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving the patient with no choice about psychoactivity—the oil was always psychoactive.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options for our Duval County customers:

Option 1—Raw, no heat. All 1,500 milligrams stays as THCa—completely non-psychoactive. The THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism. This option is compatible with work, driving, parenting, and daytime use with zero psychoactive impairment. Perfect for Duval County professionals who need to stay sharp for work at the port, teaching in Mandarin, or managing a business in Riverside.

Option 2—Fully activated, home decarboxylation. Heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC already in the formula, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO—100% legally, because decarboxylation occurs at the customer’s discretion after purchase. Duval County customers may also transfer a controlled portion of the oil from the original bottle into a second empty oven-safe glass container, decarboxylating only what they intend to use and preserving the remainder in its raw THCa form.

Option 3—Vape, auto-decarboxylation. The RSO Vape Cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available, ideal for breakthrough pain or acute anxiety episodes.

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

This design puts the potency decision entirely in the customer’s hands—aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than a one-size-fits-all approach.

Solvent-Free Production

OilWell’s RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production, as discussed in the Rick Simpson section.

The product uses organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile—a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through the OilWell website.

The Broader OilWell Product Portfolio

Beyond RSO, OilWell Cannabis produces a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach—OilWell’s most popular product. Asshole Peach is a carefully formulated experience designed to provide a euphoric, long-lasting sensation. It is particularly favored by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive. For Duval County’s significant veteran community around NAS Jacksonville and the broader military families in our area, this product has resonated deeply.

Peace Gummies—Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in a vape form for quick relief—Colin personally uses the vape to manage his insomnia and severe PTSD on an ongoing basis.

Custom creations—OilWell offers custom-made products tailored to the specific needs of individual customers. Whether it involves specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, OilWell designs targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.

Two Product Formats

OilWell offers the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil—$129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19% (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40 to 60 doses per bottle depending on serving size

RSO Vape Cartridge—$49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35% (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400 to 450°F)

When to Use Each Format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset—perfect for breakthrough moments
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration—ideal for overnight relief
Maximum bioavailability	Sublingual	13-19% absorption—most efficient use of cannabinoids
Portability and discretion	Vape	Compact, no measuring required—easy for Jaguars games or beach days
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments—perfect for titration
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment—functional for work at the port or downtown
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC—full therapeutic potential

Competitive Comparison—OilWell RSO vs. Alternatives

The following tables present factual comparisons between OilWell’s RSO formula and other RSO products. These comparisons are based on publicly available specifications and are presented for informational context.

OilWell RSO vs. Florida Medical Marijuana RSO

Dimension	Florida Medical Marijuana RSO	OilWell RSO
Cannabinoid profile	THC-only (approx. 420-600 mg THC per syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Patient-controlled potency	No—always fully psychoactive	Yes—THCa non-psychoactive until heated by customer
Access requirements	Florida Medical Marijuana Card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, ALS, MS, terminal illness, etc.	None required
Delivery	Must travel to Trulieve, Surterra, or other state dispensary	Ships directly to Duval County homes
Farm Bill compliant	No—state medical cannabis program	Yes—less than 0.3% delta-9 THC

OilWell RSO vs. Hemp CBD RSO

Dimension	Typical Hemp CBD RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	~950 mg	4,500 mg
CBG content	Minimal	3,000 mg
CBN content	Minimal	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9 THC)	Minimal	1,500 mg (converts to ~1,315 mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes—via THCa decarboxylation and delta-8 THC
Approximate price	$40-50	$129.99

Condition-Specific Usage Context for Duval County

Important disclaimer: The following usage contexts are informed by cannabinoid research cited in the GENERAL KNOWLEDGE section and by OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

For our Duval County neighbors at Mayo Clinic Jacksonville, Baptist Health, or any oncology practice:

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence, delta-9 THC nausea and vomiting evidence, CBD anxiolytic buffering

Chronic pain (fibromyalgia, arthritis, neuropathy)—common among Jacksonville’s senior population

• Daytime: 0.3 to 0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence, delta-9 THC pain evidence, beta-caryophyllene CB2 agonism, THCa COX-2 inhibition

Sleep support—for Duval County’s shift workers and insomniacs

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN—the dosage level investigated in the 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN—above the 20 mg threshold associated with reduced sleep disturbance in published research
• Evidence context: CBN sleep evidence, cannabis and sleep review literature

Anxiety and stress—for our military families, first responders, and healthcare workers

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence, CBG pharmacology, limonene entourage-effect evidence

General titration principle for Duval County customers: Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors. This is especially important for our senior community in neighborhoods like San Jose and Beauclerc, who may be taking multiple medications.

Delivery to Duval County—From Houston to Your Jacksonville Home

While we wish we could offer same-day delivery to every front porch from Palm Valley to Baldwin, our Houston-based operation means Duval County customers receive their orders via fast, reliable shipping.

Nationwide shipping to Duval County

• All 50 states where Farm Bill-compliant products are legal—including Florida and Duval County
• USPS Priority Mail (2 to 3 business days), FedEx and UPS Ground (3 to 5 business days)
• Discreet packaging with no cannabis branding visible—important for privacy-conscious customers in conservative areas of Duval County
• Tracking provided for all orders—watch it travel from Houston to Jacksonville
• Temperature-stable packaging for summer shipments—crucial for Jacksonville’s 95°F summer days
• Signature-required option available

International shipping

OilWell ships internationally and has delivered to multiple countries. The THCa legal framework makes this possible: because the product contains less than 0.3% delta-9 THC at the point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill.

• All international packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes
• Minimum flat-fee shipping applies; excessive international shipping costs are billed to the customer
• The customer is responsible for verifying legality in their jurisdiction and accepts all customs and legal risk

The significance of this access for Duval County cannot be overstated. Rick Simpson could not ship his oil anywhere—it was Schedule I, illegal to produce, possess, or transport. A cancer patient in Jacksonville’s Southside, a chronic pain sufferer in Ponte Vedra, or a veteran in Arlington can now access the same clinical-strength multi-cannabinoid RSO formula that a Houston resident receives via same-day delivery. We’ve built a product that can move across state lines legally—completing a piece of Rick Simpson’s vision that prohibition made impossible during his lifetime.

OilWell’s PANDEM1C SEO technology—a proprietary system with 14 million distinct geopolitical locations in its database and over 300 AI models—drives organic search visibility, making OilWell products discoverable to Duval County patients searching for RSO in their own terms.

How the OilWell Formulas Connect to the Evidence

Every cannabinoid in OilWell’s formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile in the GENERAL KNOWLEDGE section. Every terpene—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—is covered with preclinical and review-level evidence.

The formulas published in this guide are not standalone product listings. They are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to the current evidence base.

The GENERAL KNOWLEDGE section’s evidence hierarchy, overstatement warnings, and safety notes apply equally to OilWell’s own products. This document does not exempt OilWell from the same evidence standards applied to the broader cannabinoid field. That is intentional. OilWell’s position—as stated by Colin Valencia in 2019—is that people deserve the best possible version of the information so they can give it a fair shot and decide for themselves whether it is right or wrong for them.

OilWell Cannabis is more than a brand—it is a promise to our Duval County customers that we will always strive to deliver the best, most thoughtful cannabis products available. We are not here to follow trends. We are here to set them. And as we continue to grow, our focus remains on maintaining the same level of integrity, creativity, and commitment that has defined us from the day Bentley got up, walked across the room, and brought his ball to play.

MEDIA RECOGNITION AND COMMUNITY IMPACT

Colin Valencia—Houston’s Authority, Serving Duval County

Between September 2019 and April 2023, ABC13 Houston (KTRK) featured Colin Valencia and OilWell Cannabis in seven distinct news segments. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers.

What this means for Duval County: While these features aired in Houston, they establish a media credibility record that transcends geography. When you’re considering a cannabis product in Jacksonville, you want to know you’re buying from a company that has been vetted by major-market media—not just social media hype. ABC13’s repeated return to Colin as their primary cannabis expert demonstrates that his knowledge, honesty, and community commitment have been independently verified by professional journalists.

The Seven ABC13 Features—A Credibility Record

1. September 2019—CBD Business Boom featuring the foundational quote: “I’m not trying to sell people snake oil…”
2. March 2021—Entrepreneur creates direct-to-consumer business, featuring Colin helping other entrepreneurs
3. May 2021—Delta-8 THC investigation with the iconic “Maybe you want to get high” exchange
4. August 2021—COVID vaccine giveaway of $35,000 in product
5. October 2021—Delta-8 ban coverage showing Colin proactively removing products before enforcement
6. October 2022—Biden pardon feature revealing Colin’s personal marijuana conviction history
7. April 2023—4/20 feature with “Renaissance” framing of the cannabis industry

The Through-Line for Duval County

The media record reveals five consistent themes:

Consistency across years. Through every legal shift and market change, ABC13 returned to Colin as their trusted source.

Breadth of expertise. From business to medicine to law to community health, Colin has spoken to it all.

Community action. Whether giving away $35,000 in product to encourage vaccination or warning competitors about legal changes, OilWell acts on principle.

Personal stakes. Colin’s own conviction history means he’s not just selling products—he’s building the industry he wishes had existed when he needed it.

Evolution. From “local wholesaler” in 2019 to industry Renaissance leader in 2023, the media record tracks real growth.

These features are not marketing materials. They are independently produced, editorially controlled news segments from a major-market ABC affiliate. That is the kind of recognition that cannot be purchased—it can only be earned. For Duval County customers, this means you’re choosing a brand that has been vetted by professional journalists over four years of intense scrutiny.

GENERAL KNOWLEDGE

Research Method and Evidence Weighting

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters because the evidence base is not evenly distributed. Of the compounds listed, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature.

Institutional Baseline from NIH and Related Sources

• NCCIH states that the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. It also notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research.
• NCCIH emphasizes that the FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals.
• Safety concerns repeatedly highlighted include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination or labeling inaccuracy, and THC-vape lung-injury concerns.
• NCCIH specifically warns that over-the-counter CBD products may differ from their labels and that CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions.

Cannabinoids—Evidence Profiles

CBD (Cannabidiol)

• Strongest human evidence in seizure disorders (Epidiolex FDA approval)
• 2024 systematic review shows statistically significant anxiolytic signal but limited clinical sample
• 2024 pain review finds promising but heterogeneous evidence
• 2023 insomnia review finds methodologically weak literature
• 2023 systematic review finds real signal for liver enzyme elevation and possible drug-induced liver injury
• Bottom line: Most evidence-developed nonintoxicating cannabinoid, but strong evidence concentrated in specific indications

CBG (Cannabigerol)

• Mostly review-level and preclinical; human evidence remains sparse
• Pharmacology shows interactions with cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A-related signaling
• Potential research areas include neurologic disorders, inflammatory bowel disease, and antibacterial activity
• Bottom line: Promising minor cannabinoid with limited clinical validation

Delta-8 THC

• Pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC
• 2022 review concludes broadly similar pharmacokinetic and pharmacodynamic behavior to delta-9 THC but less potent
• 2023 scoping review finds evidence base dominated by animal studies, product chemistry, use reports, and public-health concerns
• Bottom line: Psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and manufacturing-quality concerns

THCa (Tetrahydrocannabinolic Acid)

• Acidic precursor of THC; may represent large share of THC-related content in raw plant material
• Does not produce psychoactive effects associated with THC if molecule stays in acidic form
• In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities
• Bottom line: Highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage

Delta-9 THC

• Strongest human evidence among psychoactive cannabinoids but also clearest adverse-effect burden
• NCCIH identifies relevance to chemotherapy-related nausea/vomiting, HIV/AIDS appetite/weight loss, and some MS/pain outcomes
• 2022 systematic review finds high THC products may provide short-term pain benefit but increase dizziness, sedation, nausea, and discontinuation
• 2025 systematic review finds consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder
• Bottom line: Legitimate therapeutic relevance in some settings, but carries clearest intoxication, psychiatric, and dose-related safety liabilities

CBN (Cannabinol)

• Marketed for sleep and sedation, but clinical support far weaker than reputation
• 2021 narrative review screened 99 human-study abstracts, reviewed 8 full-text articles, found no clinical trials using validated sleep questionnaires or polysomnography
• 2024 updated review concludes overall cannabinoid sleep research still doesn’t match scale of real-world use
• Bottom line: Cultural reputation stronger than current clinical evidence base

CBC (Cannabichromene)

• Emerging, intriguing, and still overwhelmingly preclinical or review-based
• 2024 focused review argues distinct pharmacodynamics, pharmacokinetics, and receptor behavior
• Highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting
• Bottom line: Scientifically credible minor cannabinoid deserving more research, not already-validated clinical active

Terpenes—Evidence Profiles

Limonene

• Largely review and preclinical, with useful safety literature
• 2021 review describes multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities
• Safety note: limonene oxidation products are clinically relevant contact allergens
• Bottom line: Biologically active but cannabis-specific therapeutic claims should stay conservative

Myrcene

• Mostly preclinical, with very limited human evidence
• 2021 review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties but explicitly states human studies lacking
• Bottom line: Plausible bioactivity, but compound-specific clinical claims remain ahead of definitive human proof

Caryophyllene

• Among most mechanistically interesting due to direct cannabinoid-system relevance
• 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist
• Bottom line: Strongest candidate for terpene with cannabinoid-system significance, but not clinically proven

Pinene

• Promising preclinical literature, weak human clinical confirmation
• 2021 review on pinene and linalool found antioxidant, anti-inflammatory, neuroprotective signals but emphasized lack of well-designed clinical trials
• Bottom line: Deserves scientific attention, but strong cognition-related claims are exploratory

Linalool

• Substantial preclinical interest, limited direct clinical confirmation
• 2021 brain-health review found enough preclinical signal to justify continued investigation
• Safety note: oxidized linalool hydroperoxides are recognized allergens
• Bottom line: Scientifically credible but should be described cautiously

Humulene

• Translationally interesting, but still early
• 2024 scoping review found broad preclinical evidence for anti-inflammatory effects, some rodent work suggesting cannabimimetic properties
• Bottom line: Interesting research target, but far from clinically settled

Terpinolene

• One of least clinically characterized
• 2021 systematic review concluded evidence base dominated by in silico, in vitro, and animal studies
• Bottom line: Biologically interesting but especially underdeveloped clinically

Research Limits and Interpretation

• Evidence base is highly uneven—CBD and delta-9 THC support most detailed statements; others require more caution
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable
• Minor cannabinoids and terpenes are commercially interesting because underexplored, but claims often become inflated
• Product quality matters as much as molecule identity—labeling inaccuracies, contamination, synthesis byproducts, and dose variability all affect interpretation
• For THCa, chemistry is destiny: storage and heating can change exposure profile by converting acidic cannabinoids into neutral cannabinoids

Common Overstatements to Avoid

• Overstatement: CBN is a clinically proven sleep cannabinoid.
  More accurate: Specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified.

• Overstatement: Myrcene is a proven human sedative that reliably explains couch-lock.
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited.

• Overstatement: Terpenes in general have proven entourage effects in patients.
  More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific.

• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing the effective exposure.

• Overstatement: Delta-8 THC is safe because it is hemp-derived.
  More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns.

Practical Takeaways for the Formulas

• Most evidence-developed actives: CBD and delta-9 THC
• Delta-8 THC is not trivial or purely mild—it is a psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC
• THCa meaningfully changes with processing and should not be interpreted the same way in raw, gently handled, and heated formats
• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC
• The listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported

RSO SUBLINGUAL OIL—THE COMPLETE FORMULA

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Format: 30mL bottle with graduated dropper (0.1mL increments)
• Carrier: Organic MCT oil
• Active per mL: 553mg cannabinoids
• Onset: 15-45 minutes
• Duration: 4-6 hours
• Bioavailability: 13-19%
• Price: $129.99

What this means for Duval County: This is 16.5 times more total cannabinoids than typical hemp RSO products. The graduated dropper lets you measure precisely whether you’re starting at 55mg (0.1mL) or using a full 553mg dose. The MCT oil base means no harsh solvent taste—just a clean, neutral flavor that works sublingually or can be added to your coffee at the Jax Beach Pier.

RSO VAPE CARTRIDGE—THE COMPLETE FORMULA

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1 Gram 510-thread cartridge
• Total cannabinoids: 900mg+
• Onset: 1-2 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35%
• Price: $49.99

What this means for Duval County: The vape format auto-decarboxylates THCa at 400-450°F, delivering instant activated THC with each puff. Perfect for breakthrough pain during a round at TPC Sawgrass, acute anxiety before a presentation downtown, or nausea that hits suddenly. The 510-thread works with any standard vape battery available at shops throughout Jacksonville.

TERPENE PROFILE (BOTH PRODUCTS)

• Limonene (citrus-bright)—for mood elevation, complements Jacksonville’s sunny disposition
• Myrcene—for relaxation, perfect for unwinding after a day on the St. Johns River
• Caryophyllene (β-caryophyllene, pepper/spice)—direct CB2 agonist for anti-inflammatory support
• Pinene (forest-fresh)—for clarity, reminiscent of Florida’s pine forests
• Linalool (floral, lavender)—for calm, easing tension after hurricane season stress
• Humulene (earthy, woody)—for inflammation support
• Terpinolene (piney, fruity, sparkling)—adds complexity to the entourage effect

Why this matters in Duval County: Florida’s terpene-rich environment—from citrus groves to pine forests—has trained our noses and our endocannabinoid systems to respond to these compounds. The terpene profile connects our product to the natural pharmacopeia that surrounds us.

A FINAL WORD TO OUR DUVAL COUNTY FAMILY

We know Jacksonville. We know the pride you feel when the Jaguars win at TIAA Bank Field. We know the relief of a cool breeze coming off the Atlantic at Jax Beach. We know the stress of watching a hurricane track toward our coast. We know the pain of losing someone to cancer at Mayo Clinic or Baptist Health. We know the struggles of veterans returning to civilian life near NAS Jacksonville. We know the daily grind of working at the port, in healthcare, in hospitality, in every sector that makes Duval County thrive.

We didn’t create OilWell Cannabis to sell you something. We created it because Bentley’s story taught us that cannabinoids can do what pharmaceuticals cannot. Because Colin’s benzo withdrawal taught us that these compounds can literally save lives. Because every day, we hear from someone in Jacksonville, Atlantic Beach, Neptune Beach, or Orange Park who has been failed by conventional medicine and is desperately searching for alternatives.

This guide represents our commitment to you: no snake oil, no false hope, just the best possible version of the research so you can make an informed decision about whether it’s right or wrong for you. We publish our formulas because Rick Simpson taught us that medicine should be accessible. We lab-test everything because the Texas Medical Center taught us that precision matters. We offer both raw and decarboxylated options because we know that some days you need to function at 100% and other days you need full-strength relief.

From our Houston home to your Jacksonville doorstep, we’re here to answer your questions, provide the evidence, and let you decide. Because at the end of the day, Bentley taught us the most important lesson: dogs don’t respond to placebo, and neither should you.

Contact us:

• Phone: (832) 416-2816
• Email: [email protected]
• Website: https://oilwellcbd.com/

We ship to every corner of Duval County. We answer every question. We’re here when you need us.

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Consult your healthcare provider before use, especially if you have a medical condition, take medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while using psychoactive cannabinoids. Keep out of reach of children. Buyer assumes responsibility for compliance with local laws. Void where prohibited.

Age Requirement: Must be 21 years of age or older to purchase RSO products.

Legal Compliance: All products contain less than 0.3% delta-9 THC by dry weight and are derived from industrial hemp, making them legal under the 2018 Farm Bill and Florida state law. Customers are responsible for verifying local regulations regarding THCa conversion and use.